<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02011386</url>
  </required_header>
  <id_info>
    <org_study_id>MANGO</org_study_id>
    <nct_id>NCT02011386</nct_id>
  </id_info>
  <brief_title>Novel MRI ANd Biomarkers in GOlimumab-treated Patients With Axial Spondyloarthritis</brief_title>
  <acronym>MANGO</acronym>
  <official_title>Improved Monitoring and Prediction of Clinical Response and Disease Course During Golimumab Therapy of Patients With Axial Spondyloarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Susanne Juhl Pedersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates different criteria for remission based on MRI and circulating
      biomarkers for inflammation, cartilage, connective tissue and bone turnover in patients with
      axial spondyloarthritis treated with Golimumab. Furthermore, the study also investigates
      factors that affect disease activity, function and participation by use of different
      questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fulfillment of BASDAI50 (i.e. reduction of 50%)</measure>
    <time_frame>Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in MRI assessment (score)</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number (percentage) of patients with ASDAS response</measure>
    <time_frame>Week 16 and 52</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Axial Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <description>Treatment: Injection Golimumab 50 mg every month on the same date</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Treatment: Injection Golimumab 50 mg every month on the same date</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with axial spondyloarthritis with moderate to high disease activity (BASDAI &gt;= 40
        mm), who are going to start treatment with tumor-necrosis-factor-alpha inhibitor.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Axial spondyloarthritis according to the ASAS classification criteria

          -  Sacroiliitis on conventional X-rays or MRI.

          -  Disease activity assessed by BASDAI &gt;40 mm despite treatment with NSAID.

          -  Clinical indication for tumor-necrosis-factor-alpha inhibitor treatment by the
             treating physician.

        Exclusion Criteria:

          -  No contraindications for tumor-necrosis-factor-alpha inhibitor

          -  No contraindications for MRI

          -  No contraindications in participation in a study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikkel Østergaard, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glostrup Hospital, University of Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mikkel Østergaard, Professor</last_name>
    <phone>+4521603865</phone>
    <email>mo@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susanne J Pedersen, MD, PhD</last_name>
    <phone>+4541431326</phone>
    <email>sjp@dadlnet.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Frederiksberg Bispebjerg Hospitals, Dep. of Rheumatology</name>
      <address>
        <city>Copenhagen</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bente Jensen, Consultant</last_name>
      <phone>+4538163816</phone>
      <email>Bente.Jensen.06@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glostrup Hospital, Dep. of Rheumatology</name>
      <address>
        <city>Copenhagen</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital, Dep. of Radiology</name>
      <address>
        <city>Copenhagen</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lone Balding, Consultant</last_name>
      <phone>+4544884488</phone>
      <email>lone.balding@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital, Dep. of Rheumatology</name>
      <address>
        <city>Copenhagen</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ole R Madsen, Consultant</last_name>
      <phone>+4539773977</phone>
      <email>Ole.Rintek.Madsen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nordsjællands Hospital Hillerød, Dep. of Rheumatology</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesper Nørregaard, Consultant</last_name>
      <phone>+4548294829</phone>
      <email>Jesper.Noerregaard.02@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Køge Hospital, Dep. of Rheumatology</name>
      <address>
        <city>Køge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Stoltenberg, Consultant</last_name>
      <phone>+4556631500</phone>
      <email>mbst@regionsjaelland.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2013</study_first_posted>
  <last_update_submitted>December 10, 2013</last_update_submitted>
  <last_update_submitted_qc>December 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Susanne Juhl Pedersen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

